EUFOREUM Berlin 2023: Optimizing care for type 2 inflammatory diseases from clinic to AI: A pediatric focus.
AD
EUFOREA
T2‐inflammation
allergic rhinitis
asthma
pediatrics
rhinosinusitis
Journal
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
ISSN: 1399-3038
Titre abrégé: Pediatr Allergy Immunol
Pays: England
ID NLM: 9106718
Informations de publication
Date de publication:
Jul 2024
Jul 2024
Historique:
revised:
04
06
2024
received:
16
02
2024
accepted:
12
06
2024
medline:
1
7
2024
pubmed:
1
7
2024
entrez:
1
7
2024
Statut:
ppublish
Résumé
The European Forum for Research and Education in Allergy and Airways diseases (EUFOREA) organized its bi-annual forum EUFOREUM in Berlin in November 2023. The aim of EUFOREUM 2023 was to highlight pediatric action plans for prevention and optimizing care for type 2 inflammatory conditions starting in childhood, with a focus on early-stage diagnosis, ensuring neither under- nor overdiagnosis, optimal care, and suggestions for improvement of care. EUFOREA is an international not-for-profit organization forming an alliance of all stakeholders dedicated to reducing the prevalence and burden of chronic respiratory diseases through the implementation of optimal patient care via educational, research, and advocacy activities. The inclusive and multidisciplinary approach of EUFOREA was reflected in the keynote lectures and faculty of the virtual EUFOREUM 2023 (www.euforea.eu/euforeum) coming from the pediatric, allergology, pulmonology, ENT, dermatology, primary health care fields and patients around the central theme of type 2 inflammation. As most type 2 inflammatory conditions may start in childhood or adolescence, and most children have type 2 inflammation when suffering from a respiratory or skin disease, the moment has come to raise the bar of ambitions of care, including prevention, remission and disease modification at an early stage. The current report provides a comprehensive overview of key statements by the faculty of the EUFOREUM 2023 and the ambitions of EUFOREA allowing all stakeholders in the respiratory field to be updated and ready to join forces in Europe and beyond.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14183Informations de copyright
© 2024 The Author(s). Pediatric Allergy and Immunology published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
De Prins L, Raap U, Mueller T, Schmid‐Grendelmeier P, et al. White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA. Front Allergy. 2022;3:889221. doi:10.3389/falgy.2022.889221
Claeys N, Teeling MT, Legrand P, et al. Patients unmet needs in chronic rhinosinusitis with nasal polyps care: a patient advisory board statement of EUFOREA. Front Allergy. 2021;2:761388. doi:10.3389/falgy.2021.761388
Pugin B, Deneyer L, Bachert C, et al. Patient advisory board for chronic rhinosinusitis – a EUFOREA initiative. Rhinology. 2019;57(5):331‐335. doi:10.4193/Rhin19.012
Kolkhir P, Akdis CA, Akdis M, et al. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs. Nat Rev Drug Discov. 2023;22(9):743‐767. doi:10.1038/s41573-023-00750-1
Hellings PW, Borrelli D, Pietikainen S, et al. European summit on the prevention and self‐management of chronic respiratory diseases: report of the European Union Parliament summit (29 march 2017). Clin Transl Allergy. 2017;7:49. doi:10.1186/s13601-017-0186-3
Hellings PW, Lau S, Scadding GK, et al. EUFOREA summit in Brussels 2023: inspiring the future of allergy & respiratory care. Front Allergy. 2023;4:1236977. doi:10.3389/falgy.2023.1236977
Muraro A, Steelant B, Pietikainen S, et al. European symposium on the awareness of allergy: report of the promotional campaign in the European Parliament (26–28 April 2016). Allergy. 2017;72(2):173‐176. doi:10.1111/all.13058
Muraro A, Fokkens WJ, Pietikainen S, et al. European symposium on precision medicine in allergy and airways diseases: report of the European Union Parliament Symposium (October 14, 2015). Rhinology. 2015;53(4):303‐307. doi:10.4193/Rhino15.400
Boland GM, Meric‐Bernstam F. The role of surgeons in building a personalized medicine program. J Surg Oncol. 2015;111(1):3‐8. doi:10.1002/jso.23684
Wray NR, Lin T, Austin J, et al. From basic science to clinical application of polygenic risk scores: a primer. JAMA Psychiatry. 2021;78(1):101‐109. doi:10.1001/jamapsychiatry.2020.3049
Kaplan A, Cao H, FitzGerald JM, et al. Artificial intelligence/machine learning in respiratory medicine and potential role in asthma and COPD diagnosis. J Allergy Clin Immunol Pract. 2021;9(6):2255‐2261. doi:10.1016/j.jaip.2021.02.014
Bachtiger P, Petri CF, Scott FE, et al. Point‐of‐care screening for heart failure with reduced ejection fraction using artificial intelligence during ECG‐enabled stethoscope examination in London, UK: a prospective, observational, multicentre study. Lancet Digit Health. 2022;4(2):e117‐e125. doi:10.1016/S2589-7500(21)00256-9
Gordon HS, Solanki P, Bokhour BG, Gopal RK. “I'm not feeling like I'm part of the conversation” patients' perspectives on communicating in clinical video telehealth visits. J Gen Intern Med. 2020;35(6):1751‐1758. doi:10.1007/s11606-020-05673-w
Diamant Z, Jesenak M, Hanania NA, et al. EUFOREA pocket guide on the diagnosis and management of asthma: an educational and practical tool for general practitioners, non‐respiratory physicians, paramedics and patients. Respir Med. 2023;218:107361. doi:10.1016/j.rmed.2023.107361
van Beveren GJ, Said H, van Houten MA, Bogaert D. The respiratory microbiome in childhood asthma. J Allergy Clin Immunol. 2023;152(6):1352‐1367. doi:10.1016/j.jaci.2023.10.001
Khaleva E, Rattu A, Brightling C, et al. Development of core outcome measures sets for paediatric and adult severe asthma (COMSA). Eur Respir J. 2023;61(4):2200606. doi:10.1183/13993003.00606-2022
Trujillo J, Lunjani N, Ryan D, O'Mahony L. Microbiome‐immune interactions and relationship to asthma severity. J Allergy Clin Immunol. 2022;149(2):533‐534. doi:10.1016/j.jaci.2021.12.774
Gene editing of microbiome may help prevent asthma in children. States News Service, 31 Aug. 2023, p. NA. Gale OneFile: Health and Medicine. link.gale.com/apps/doc/A762947280/HRCA?u=anon~fa9c1de3&sid=sitemap&xid=325e5880. Accessed December 9, 2023.
Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020;578(7794):229‐236. doi:10.1038/s41586-020-1978-5
Voraphani N, Stern DA, Ledford JG, et al. Circulating CC16 and asthma: a population‐based, multicohort Study from early childhood through adult life. Am J Respir Crit Care Med. 2023;208(7):758‐769. doi:10.1164/rccm.202301-0041OC
Frendø M, Håkansson K, Schwer S, et al. Asthma in ear, nose, and throat primary care patients with chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2016;30(3):67‐71. doi:10.2500/ajra.2016.30.4304
Lau S, Matricardi PM, Wahn U, Lee YA, Keil T. Allergy and atopy from infancy to adulthood: messages from the German birth cohort MAS. Ann Allergy Asthma Immunol. 2019;122(1):25‐32. doi:10.1016/j.anai.2018.05.012
Keil T, Bockelbrink A, Reich A, et al. The natural history of allergic rhinitis in childhood. Pediatr Allergy Immunol. 2010;21(6):962‐969. doi:10.1111/j.1399-3038.2010.01046.x
Warren CM, Jiang J, Gupta RS. Epidemiology and burden of food allergy. Curr Allergy Asthma Rep. 2020;20(2):6. doi:10.1007/s11882-020-0898-7
Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004;113(5):925‐931. doi:10.1016/j.jaci.2004.01.778
Grabenhenrich LB, Gough H, Reich A, et al. Early‐life determinants of asthma from birth to age 20 years: a German birth cohort study. J Allergy Clin Immunol. 2014;133(4):979‐988. doi:10.1016/j.jaci.2013.11.035
Rochat MK, Illi S, Ege MJ, et al. Allergic rhinitis as a predictor for wheezing onset in school‐aged children. J Allergy Clin Immunol. 2010;126(6):1170‐1175.e2. doi:10.1016/j.jaci.2010.09.008
Marenholz I, Nickel R, Rüschendorf F, et al. Filaggrin loss‐of‐function mutations predispose to phenotypes involved in the atopic march. J Allergy Clin Immunol. 2006;118(4):866‐871. doi:10.1016/j.jaci.2006.07.026
Marenholz I, Bauerfeind A, Esparza‐Gordillo J, et al. The eczema risk variant on chromosome 11q13 (rs7927894) in the population‐based ALSPAC cohort: a novel susceptibility factor for asthma and hay fever. Hum Mol Genet. 2011;20(12):2443‐2449. doi:10.1093/hmg/ddr117
Marín D, Orozco LY, Narváez DM, et al. Characterization of the external exposome and its contribution to the clinical respiratory and early biological effects in children: the PROMESA cohort study protocol. PLoS One. 2023;18(1):e0278836. doi:10.1371/journal.pone.0278836
Guillien A, Cadiou S, Slama R, Siroux V. The exposome approach to decipher the role of multiple environmental and lifestyle determinants in asthma. Int J Environ Res Public Health. 2021;18(3):1138. doi:10.3390/ijerph18031138
Agier L, Basagaña X, Maitre L, et al. Early‐life exposome and lung function in children in Europe: an analysis of data from the longitudinal, population‐based HELIX cohort. Lancet Planet Health. 2019;3(2):e81‐e92. doi:10.1016/S2542-5196(19)30010-5
Davidson EJ, Yang IV. Role of epigenetics in the development of childhood asthma. Allergy Clin Immunol. 2018;18(2):132‐138. doi:10.1097/ACI.0000000000000429
Colwell ML, Townsel C, Petroff RL, Goodrich JM, Dolinoy DC. Epigenetics and the exposome: DNA methylation as a proxy for health impacts of prenatal environmental exposures. Exp Dermatol. 2023;3(1):osad001. doi:10.1093/exposome/osad001
Scholtens S, Postma DS, Moffatt MF, et al. Novel childhood asthma genes interact with in utero and early‐life tobacco smoke exposure. J Allergy Clin Immunol. 2014;133(3):885‐888. doi:10.1016/j.jaci.2013.08.049
Fleischer DM, Sicherer S, Greenhawt M, et al. Consensus communication on early peanut introduction and the prevention of peanut allergy in high‐risk infants. Allergy. 2015;70(10):1193‐1195. doi:10.1111/all.12687
Scadding GK, McDonald M, Backer V, et al. Pre‐asthma: a useful concept for prevention and disease‐modification? A EUFOREA paper. Part 1—allergic asthma. Front Allergy. 2023;4:1291185. doi:10.3389/falgy.2023.1291185
Hellings PW, Scadding G, Bachert C, et al. EUFOREA treatment algorithm for allergic rhinitis. Rhinology. 2020;58(6):618‐622. doi:10.4193/Rhin20.246
Scadding GK, Smith PK, Blaiss M, et al. Allergic rhinitis in childhood and the new EUFOREA algorithm. Front Allergy. 2021;2:706589. doi:10.3389/falgy.2021.706589
Kharaba Z, Feghali E, El Husseini F, et al. An assessment of quality of life in patients with asthma through physical, emotional, social, and occupational aspects. A cross‐sectional study. Front Public Health. 2022;10:883784. doi:10.3389/fpubh.2022.883784
Scadding G, Bousquet J, Bachert C, et al. Rhinology future trends: 2017 EUFOREA debate on allergic rhinitis. Rhinology. 2019;57(1):49‐56. doi:10.4193/Rhin18.076
Mygind N, Dahl R, Nielsen LP. Effect of nasal inflammation and of intranasal anti‐inflammatory treatment on bronchial asthma. Respir Med. 1998;92(3):547‐549. doi:10.1016/s0954-6111(98)90306-7
Backer V, Cardell LO, Lehtimäki L, et al. Multidisciplinary approaches to identifying and managing global airways disease: expert recommendations based on qualitative discussions. Front Allergy. 2023;4:1052386. doi:10.3389/falgy.2023.1052386
Mansur AH, Prasad N. Management of difficult‐to‐treat asthma in adolescence and young adults. Breathe (Sheff). 2023;19(1):220025. doi:10.1183/20734735.0025-2022
Hellings PW, Pugin B, Mariën G, et al. Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI‐Abeforcal‐EUFOREA statement. Clin Transl Allergy. 2019;9:1. doi:10.1186/s13601-019-0243-1
Virchow JC, Backer V, de Blay F, et al. Defining moderate asthma exacerbations in clinical trials based on ATS/ERS joint statement. Respir Med. 2015;109(5):547‐556. doi:10.1016/j.rmed.2015.01.012
Backer V, Virchow JC, Villesen HH, Fejerskov PA, Riis B, De Blay F. HDM sublingual AIT tablet is well‐tolerated and effective in partly and uncontrolled allergic asthma Vibeke. Eur Respir J. 2014;44:P298.
Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010;2010(12):CD002893. doi:10.1002/14651858.CD002893.pub2
Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;2007(1):CD001936. doi:10.1002/14651858.CD001936.pub2
Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy Clin Immunol. 2016;137(2):339‐349.e10. doi:10.1016/j.jaci.2015.12.1298
Roberts G, Pfaar O, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018;73(4):765‐798. doi:10.1111/all.13317
Ryan D, Gerth van Wijk R, Angier E, et al. Challenges in the implementation of the EAACI AIT guidelines: a situational analysis of current provision of allergen immunotherapy. Allergy. 2018;73(4):827‐836. doi:10.1111/all.13264
Matricardi PM, Illi S, Grüber C, et al. Wheezing in childhood: incidence, longitudinal patterns and factors predicting persistence. Eur Respir J. 2008;32(3):585‐592. doi:10.1183/09031936.00066307
Xu CJ, Scheltema NM, Qi C, et al. Infant RSV immunoprophylaxis changes nasal epithelial DNA methylation at 6 years of age. Pediatr Pulmonol. 2021;56(12):3822‐3831. doi:10.1002/ppul.25643
Simões EAF, Center KJ, Tita ATN, et al. Prefusion F protein‐based respiratory syncytial virus immunization in pregnancy. N Engl J Med. 2022;386(17):1615‐1626. doi:10.1056/NEJMoa2106062
Phipatanakul W, Mauger DT, Guilbert TW, et al. Preventing asthma in high risk kids (PARK) with omalizumab: design, rationale, methods, lessons learned and adaptation. Contemp Clin Trials. 2021;100:106228. doi:10.1016/j.cct.2020.106228
Spergel JM, Du Toit G, Davis CM. Might biologics serve to interrupt the atopic march? J Allergy Clin Immunol. 2023;151(3):590‐594. doi:10.1016/j.jaci.2023.01.001
Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet. 2022;400(10356):908‐919. doi:10.1016/S0140-6736(22)01539-2
Kleniewska P, Kopa‐Stojak PN, Hoffmann A, Pawliczak R. The potential immunomodulatory role of the gut microbiota in the pathogenesis of asthma: an in vitro study. Sci Rep. 2023;13(1):19721. doi:10.1038/s41598-023-47003-0
Hamelmann E, Hammerby E, Scharling KS, Pedersen M, Okkels A, Schmitt J. Quantifying the benefits of early sublingual allergen immunotherapy tablet initiation in children. Allergy. 2023;79:1018‐1027. doi:10.1111/all.15985
Bacharier LB, Jackson DJ. Biologics in the treatment of asthma in children and adolescents. J Allergy Clin Immunol. 2023;151(3):581‐589. doi:10.1016/j.jaci.2023.01.002
van Dijk YE, Rutjes NW, Golebski K, et al. Developments in the management of severe asthma in children and adolescents: focus on dupilumab and tezepelumab. Paediatr Drugs. 2023;25(6):677‐693. doi:10.1007/s40272-023-00589-4
Butala S, Paller AS. Biologics in the management of childhood atopic dermatitis. J Allergy Clin Immunol. 2023;151(3):681‐685. doi:10.1016/j.jaci.2023.01.010
Zuberbier T, Peter J, Staubach P, Chularojanamontri L, Kulthanan K. Potential therapeutic approaches for chronic Urticaria: beyond H1‐antihistamines and biologics. J Allergy Clin Immunol Pract. 2023;11(8):2265‐2273. doi:10.1016/j.jaip.2023.06.027
Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74(12):2312‐2319. doi:10.1111/all.13875
Bachert C, Han JK, Wagenmann M, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol. 2021;147(1):29‐36. doi:10.1016/j.jaci.2020.11.013
Eger K, Amelink M, Hashimoto S, Hekking PP, Longo C, Bel EH. Overuse of oral corticosteroids, underuse of inhaled corticosteroids, and implications for biologic therapy in asthma. Respiration. 2022;101(2):116‐121. doi:10.1159/000518514
Hellings PW, Fokkens WJ, Orlandi R, et al. The EUFOREA pocket guide for chronic rhinosinusitis. Rhinology. 2023;61(1):85‐89. doi:10.4193/Rhin22.344
Hellings PW, Akdis CA, Bachert C, et al. EUFOREA rhinology research forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis. Rhinology. 2017;55(3):202‐210. doi:10.4193/Rhin17.028
Fokkens WJ, Viskens AS, Backer V, et al. EPOS/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023. Rhinology. 2023;61:194‐202. doi:10.4193/Rhin22.489
Cohn L. Can asthma biologics change the course of disease and induce drug‐free remission? J Allergy Clin Immunol. 2022;150(1):59‐61. doi:10.1016/j.jaci.2022.04.005
Santos‐Valente E, Buntrock‐Döpke H, Abou Taam R, et al. Biologicals in childhood severe asthma: the European PERMEABLE survey on the status quo. ERJ Open Res. 2021;7(3):143‐2021. doi:10.1183/23120541.00143-2021
Menzies‐Gow A, Szefler SJ, Busse WW. The relationship of asthma biologics to remission for asthma. J Allergy Clin Immunol Pract. 2021;9(3):1090‐1098. doi:10.1016/j.jaip.2020.10.035
Hellings PW, Fokkens WJ, Bachert C, et al. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – a EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement. Allergy. 2017;72(9):1297‐1305. doi:10.1111/all.13162
Altrichter S, Staubach P, Pasha M, et al. An open‐label, proof‐of‐concept study of lirentelimab for antihistamine‐resistant chronic spontaneous and inducible urticaria. J Allergy Clin Immunol. 2022;149(5):1683‐1690.e7. doi:10.1016/j.jaci.2021.12.772
Zuberbier T, Bernstein JA, Maurer M. Chronic spontaneous urticaria guidelines: what is new? J Allergy Clin Immunol. 2022;150(6):1249‐1255. doi:10.1016/j.jaci.2022.10.004
Metz M, Kolkhir P, Altrichter S, et al. Mast cell silencing: a novel therapeutic approach for urticaria and other mast cell‐mediated diseases. Allergy. 2024;79(1):37‐51. doi:10.1111/all.15850
Bernstein JA, Maurer M, Saini SS. BTK signaling‐a crucial link in the pathophysiology of chronic spontaneous urticaria. J Allergy Clin Immunol. 2023;153(5):1229‐1240. doi:10.1016/j.jaci.2023.12.008
Kaplan A, Lebwohl M, Giménez‐Arnau AM, Hide M, Armstrong AW, Maurer M. Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances. Allergy. 2023;78(2):389‐401. doi:10.1111/all.15603
Terhorst‐Molawi D, Hawro T, Grekowitz E, et al. Anti‐KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria. Allergy. 2023;78(5):1269‐1279. doi:10.1111/all.15585
Kalb B, Marenholz I, Jeanrenaud ACSN, et al. Filaggrin loss‐of‐function mutations are associated with persistence of egg and milk allergy. J Allergy Clin Immunol. 2022;150(5):1125‐1134. doi:10.1016/j.jaci.2022.05.018
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345‐360. doi:10.1016/S0140-6736(20)31286-1
Schneider S, Li L, Zink A. The new era of biologics in atopic dermatitis: a review. Dermatol Pract Concept. 2021;11(4):e2021144. doi:10.5826/dpc.1104a144
Paller AS, Siegfried EC, Thaçi D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double‐blinded, placebo‐controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282‐1293. doi:10.1016/j.jaad.2020.06.054
Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44‐56. doi:10.1001/jamadermatol.2019.3336
Simpson EL, Akinlade B, Ardeleanu M. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2017;376(11):1090‐1091. doi:10.1056/NEJMc1700366
Wollenberg A, Blauvelt A, Guttman‐Yassky E, et al. Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437‐449. doi:10.1111/bjd.19574
Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242‐255. doi:10.1111/bjd.18898
Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS‐24 and LIBERTY NP SINUS‐52): results from two multicentre, randomised, double‐blind, placebo‐controlled, parallel‐group phase 3 trials. Lancet. 2019;394(10209):1638‐1650. doi:10.1016/S0140-6736(19)31881-1
Bender B, Oppenheimer J, George M, et al. Assessment of real‐world escalation to biologics in US patients with asthma. J Allergy Clin Immunol Pract. 2022;10(11):2941‐2948. doi:10.1016/j.jaip.2022.07.016
Bachert C, Sousa AR, Han JK, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count. J Allergy Clin Immunol. 2022;149(5):1711‐1721.e6. doi:10.1016/j.jaci.2021.10.040
Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595‐605. doi:10.1016/j.jaci.2020.05.032
Portnoy JM, Van Osdol T, Williams PB. Evidence‐based strategies for treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2004;4(6):439‐446. doi:10.1007/s11882-004-0009-1
Bożek A, Fischer A, Bogacz‐Piaseczynska A, Canonica GW. Adding a biologic to allergen immunotherapy increases treatment efficacy. ERJ Open Res. 2023;9(2):639‐2022. doi:10.1183/23120541.00639-2022
Yu C, Wang K, Cui X, et al. Clinical efficacy and safety of omalizumab in the treatment of allergic rhinitis: a systematic review and meta‐analysis of randomized clinical trials. Am J Rhinol Allergy. 2020;34(2):196‐208. doi:10.1177/1945892419884774
Hellings PW. From prevention to optimal treatment in chronic rhinosinusitis. Rhinology. 2018;56(4):305‐306. doi:10.4193/Rhin.18.404
Staab D, Diepgen TL, Fartasch M, et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ. 2006;332(7547):933‐938. doi:10.1136/bmj.332.7547.933
Heratizadeh A, Werfel T, Wollenberg A, et al. Effects of structured patient education in adults with atopic dermatitis: multicenter randomized controlled trial. J Allergy Clin Immunol. 2017;140(3):845‐853.e3. doi:10.1016/j.jaci.2017.01.029
Seys SF, Bousquet J, Bachert C, et al. mySinusitisCoach: patient empowerment in chronic rhinosinusitis using mobile technology. Rhinology. 2018;56(3):209‐215. doi:10.4193/Rhin17.253
Kuwabara A, Su S, Krauss J. Utilizing digital health Technologies for Patient Education in lifestyle medicine. Am J Lifestyle Med. 2019;14(2):137‐142. doi:10.1177/1559827619892547
Paller AS, Spergel JM, Mina‐Osorio P, Irvine AD. The atopic march and atopic multimorbidity: many trajectories, many pathways. J Allergy Clin Immunol. 2019;143(1):46‐55. doi:10.1016/j.jaci.2018.11.006
Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr. 2019;7:246. doi:10.3389/fped.2019.00246
Alfonso J, Pérez S, Bou R, et al. Asthma prevalence and risk factors in school children: the RESPIR longitudinal study. Allergol Immunopathol (Madr). 2020;48(3):223‐231. doi:10.1016/j.aller.2019.06.003
Sears MR. Epidemiology of childhood asthma. Lancet. 1997;350(9083):1015‐1020. doi:10.1016/S0140-6736(97)01468-2
Ferrante G, La Grutta S. The burden of pediatric asthma. Front Pediatr. 2018;6:186. doi:10.3389/fped.2018.00186
Asher MI, Rutter CE, Bissell K, et al. Worldwide trends in the burden of asthma symptoms in school‐aged children: Global Asthma Network Phase I cross‐sectional study. Lancet. 2021;398(10311):1569‐1580. doi:10.1016/S0140-6736(21)01450-1
Licari A, Magri P, De Silvestri A, et al. Epidemiology of allergic rhinitis in children: a systematic review and meta‐analysis. J Allergy Clin Immunol Pract. 2023;11(8):2547‐2556. doi:10.1016/j.jaip.2023.05.016
Meltzer EO, Blaiss MS, Derebery MJ, et al. Burden of allergic rhinitis: results from the pediatric allergies in America survey. J Allergy Clin Immunol. 2009;124(3 Suppl):S43‐S70. doi:10.1016/j.jaci.2009.05.013
Iordache A, Boruga M, Mușat O, Jipa DA, Tătaru CP, Mușat GC. Relationship between allergic rhinitis and allergic conjunctivitis (allergic rhinoconjunctivitis) – review. Rom J Ophthalmol. 2022;66(1):8‐12. doi:10.22336/rjo.2022.3
Orlova E, Smirnova L, Nesvizhsky Y, Kosenkov D, Zykova E. Acute urticaria in children: course of the disease, features of skin microbiome. Postepy Dermatol Alergol. 2022;39(1):164‐170. doi:10.5114/ada.2022.113808
Sekerel BE, Ilgun Gurel D, Sahiner UM, Soyer O, Kocaturk E. The many faces of pediatric urticaria. Front Allergy. 2023;4:1267663. doi:10.3389/falgy.2023.1267663
Peck G, Hashim MJ, Shaughnessy C, Muddasani S, Elsayed NA, Fleischer AB Jr. Global epidemiology of urticaria: increasing burden among children, females and low‐income regions. Acta Derm Venereol. 2021;101(4):adv00433. doi:10.2340/00015555-3796
Seth D, Cheldize K, Brown D, Freeman EF. Global burden of skin disease: inequities and innovations. Curr Dermatol Rep. 2017;6(3):204‐210. doi:10.1007/s13671-017-0192-7
Mehrmal S, Uppal P, Giesey RL, Delost GR. Identifying the prevalence and disability‐adjusted life years of the most common dermatoses worldwide. J Am Acad Dermatol. 2020;82(1):258‐259. doi:10.1016/j.jaad.2019.09.066
Freeman EE. A seat at the big table: expanding the role of dermatology at the World Health Organization and beyond. J Invest Dermatol. 2014;134(11):2663‐2665. doi:10.1038/jid.2014.355
Poddighe D. The prevalence of chronic spontaneous urticaria (CSU) in the pediatric population. J Am Acad Dermatol. 2019;81(5):e149. doi:10.1016/j.jaad.2019.07.068
Ertoy Karagol HI, Yilmaz O, Bakirtas A, Topal E, Demirsoy MS, Turktas I. Angioedema without urticaria in childhood. Pediatr Allergy Immunol. 2013;24(7):685‐690. doi:10.1111/pai.12118
Malbrán E, Fernández Romero D, Juri MC, Larrauri BJ, Malbrán A. Epidemiology of angioedema without wheals in an allergy and immunology center. Medicina (B Aires). 2015;75(5):273‐276.
Lumry WR, Settipane RA. Hereditary angioedema: epidemiology and burden of disease. Allergy Asthma Proc. 2020;41(Suppl 1):S08‐S13. doi:10.2500/aap.2020.41.200050